Intercell AG and Boehringer Ingelheim Vetmedica Inc Enter into Strategic Partnership to Develop Animal Vaccines Bio. Space is a DHI service.
Intercell to axe jobs after diarrhoea vax patch failure. The Austrian biotech firm said the decision was made after the candidate “did not meet the endpoints” in efficacy when it failed to protect against enterotoxigenic Escherichia coli (E coli) mediated diarrheal infections during a randomised and placebo- controlled Phase III study involving 2. Intercell expects to post a significantly higher loss for 2.
The company said the results of the study will “substantially impair” part of its intangible assets related to the program. As such, an Intercell spokesperson confirmed to in- Pharma. Technologist the firm’s intention to reduce research and development (R& D) expenses by 4.
As of May 28, 2013, Intercell Ag was acquired by Valneva SE. Intercell AG, a biotechnology company, develops and commercializes novel immunomodulatory. Intercell Completes Placement Of Eur 33.0m Senior Convertible Debt Financing. Vaccine Enhancement Patch). BioWorld Online is the news service of. Patch Fails to Boost Pandemic Flu Vaccine. Intercell announces Phase I results on its Vaccine Enhancement Patch (VEP) with Pandemic Influenza antigens.
Travellers’ Diarrhoea program while .
Definition of intercell in the Definitions. Antigen identification program and adjuvant technologies.